evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,230 questions · 1,303 findings · 326 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 73 · 5.6%GRADE not reported 21 · 1.6%Very low 497 · 38.1%Low 403 · 30.9%Moderate 245 · 18.8%High 64 · 4.9%

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Diabetes · primary immunosuppression in kidney transplant recipients

Low probably leads to lower diabetes compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Lymphoma/PTLD · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in lymphoma/PTLD compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Acne/rash · primary immunosuppression in kidney transplant recipients

Low showed no clear difference in acne/rash compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Hypercholesterolaemia · primary immunosuppression in kidney transplant recipients

Low probably leads to lower hypercholesterolaemia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Anaemia · primary immunosuppression in kidney transplant recipients

Low may leads to lower anaemia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).

1 finding from 1 review

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Thrombocytopenia · primary immunosuppression in kidney transplant recipients

Low may leads to lower thrombocytopenia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).

1 finding from 1 review

Chemotherapy plus lower‐dose radiation vs same chemotherapy plus higher‐dose radiation

Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages)

Chemotherapy plus lower‐dose radiation showed no clear difference in secondary malignant neoplasms compared with same chemotherapy plus higher‐dose radiation (low certainty).

1 finding from 1 review

Chemotherapy plus lower‐dose radiation vs same chemotherapy plus higher‐dose radiation

Death · Patients with untreated Hodgkin lymphoma (early stages)

Chemotherapy plus lower‐dose radiation showed no clear difference in death compared with same chemotherapy plus higher‐dose radiation (high certainty).

1 finding from 1 review

Chemotherapy plus lower‐dose radiation vs same chemotherapy plus higher‐dose radiation

Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)

Chemotherapy plus lower‐dose radiation showed no clear difference in progression/relapse compared with same chemotherapy plus higher‐dose radiation (high certainty).

1 finding from 1 review

Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000)

Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in numbers of participants with at least 1 clinically significant… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).

1 finding from 1 review

Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000)

Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in number of participants with WHO Grade 3 or 4 bleeding up to 30 days… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).

1 finding from 1 review

Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000)

Time to first bleeding episode (days) · People with a haematological disorder

Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in time to first bleeding episode (days) compared with higher transfusion threshold (20,000 or 30,000) (low certainty).

1 finding from 1 review

Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000)

Mortality from all causes up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in mortality from all causes up to 30 days from study entry compared with higher transfusion threshold (20,000 or 30,000) (low certainty).

1 finding from 1 review